Assess Target Product Profiles of Key Current and Future Competitors in the Psoriasis Therapeutics Market With This Report.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c66381) has announced the addition of "Therapeutic Clinical Intelligence - Psoriasis psoriasis (sôrī`əsĭs), occasionally acute but usually chronic and recurrent inflammation of the skin. The exact cause is unknown, but the disease appears to be an inherited, possibly autoimmune disorder that causes the " to their offering. The Psoriasis Therapeutic Clinical Intelligence report provides an in-depth assessment of the R&D competitive landscape for psoriasis (PsO)--from a clinical perspective. Additionally, the analysis highlights select compounds in the pipeline for Psoriatic Arthritis Psoriatic Arthritis Definition Psoriatic arthritis is a form of arthritic joint disease associated with the chronic skin scaling and fingernail changes seen in psoriasis. (PsA). The scope of the report focuses on competitive biologic and novel small molecule products in development and specifically captures key data on clinical trial design and data results for the products that have the potential to alter the market dynamics in psoriasis over the next 3-7 years. This methodological approach is intended to provide insight into the strategic opportunities and challenges, as well as the clinical hurdles facing PsO/PsA drug developers. Clients utilize the report as a resource to support key decisions including: - Analyzing the overall depth and breadth of the competitive landscape within a therapeutic area - Assessing target product profiles of key current and future competitors - Benchmarking competitor clinical trial designs and results - Developing clinical analogues to support go-no-go decisions - Identifying clinical hurdles posed by competitors - Designing clinical trials more effectively to maximize a product's penetration Reports contain synthesized syn·the·sized adj. 1. Relating to or being an instrument whose sound is modified or augmented by a synthesizer. 2. Relating to or being compositions or a composition performed on synthesizers or synthesized instruments. information and analysis of clinical development activities for key marketed and pipeline products within multiple therapeutic categories and generally include the following data points: Product Overview: Mechanism of Action, Developing Companies, Indications and Phase of Development. Clinical Trial Assessments: Detailed evaluations of completed and ongoing competitor studies that capture key elements of the study protocol including: - Trial design - Start and end dates - Study size and patient type - Number of participating sites - Dosing regimen regimen /reg·i·men/ (rej´i-men) a strictly regulated scheme of diet, exercise, or other activity designed to achieve certain ends. reg·i·men n. 1. - Endpoints - Safety and efficacy results The world-wide market for Psoriasis therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. is estimated to be valued at $1-$3 billion annually. There are currently only 3 biologic competitors vying vy·ing v. Present participle of vie. vying vie for share of this market. The Anti-TNF-a monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). -- Enbrel En·brel A trademark for the drug etanercept. etanercept Enbrel Pharmacologic class: Immunomodulator Therapeutic class: Antiarthritic Pregnancy risk category B , Humira, and Remicade -- currently dominate the moderate-to-severe psoriasis therapeutic market. However, companies are aggressively developing both novel and second-generation compounds that have the potential to challenge the competitive position of these market leaders in the future. Potential threats on the horizon include biologic therapies such as Cimzia, CNTO-1275, Golimumab, and ABT-874 in both psoriasis and/or psoriatic arthritis. Additionally, the development landscape for small molecules could produce competitive therapeutic alternatives to Anti-TNFs. Novel compounds including BMS-582949 and Apremilast have a convenience and cost advantage over the biologics due to their oral formulation formulation /for·mu·la·tion/ (for?mu-la´shun) the act or product of formulating. American Law Institute Formulation and potential attractiveness to managed care organizations and pharmacy pharmacy, art of compounding and dispensing drugs and medication. The term is also applied to an establishment used for such purposes. Until modern times medication was prepared and dispensed by the physician himself. In the 18th cent. benefit managers (payers). However it is yet to be seen if these agents will be able to demonstrate superior efficacy over the current market leaders. Companies Mentioned In This Report Include: - Enbrel (etanercept) - Humira (adalimumab) - Raptiva - Remicade (infliximab) For more information visit http://www.researchandmarkets.com/reports/c66381 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion